Pharmaceutical container and liquid composition

1. A pharmaceutical container for drug delivery, comprising:

a barrel configured to slidably receive a stopper, the pharmaceutical container exhibiting a ratio of a break loose force (BLF) relative to a glide force (GF) of BLF/GF≤2 during a break loose and glide force test and a total glide force variation TGFV=GF max −GF min measured when the stopper is moved from a start position to its end position is TGFV<2 N, the stopper having a proximal end suitable for contacting a plunger rod, a distal end suitable for contacting a pharmaceutical composition, a circumferential surface at least partially suitable for contacting an inner surface of the barrel, and one or more annular protrusions contacting the inner surface of the barrel when the stopper moves in a distal direction, the one or more annular protrusions each having a rising edge and a falling edge in a proximal-distal direction, the rising edge of a most proximal annular protrusion and the inner surface of the barrel span angle X in the distal direction, the falling edge of a most distal annular protrusion and the inner surface span an angle A in a proximal direction, and the ratio X/A is at least 1.05, wherein the stopper has a circumferential surface with a water contact angle θc and the inner surface of the barrel has a water contact angle θ I , wherein a ratio of θ C /θ I >0.9.

2. The pharmaceutical container of claim 1 , wherein the ratio X/A is from >1.1 to 1.7.

3. The pharmaceutical container of claim 1 , wherein A is from 130° to 170°.

4. The pharmaceutical container of claim 1 , wherein the stopper has at least two annular protrusions.

5. The pharmaceutical container of claim 1 , wherein the pharmaceutical container is selected from the group consisting of a syringe, a cartridge and a carpule.

6. The pharmaceutical container of claim 1 , wherein the inner surface of the barrel has a water contact angle of at least 80°.

7. The pharmaceutical container of claim 1 , wherein the inner surface of the barrel has at least one of:

a surface roughness Ra of less than 100 nm;

a surface roughness Rms of less than 150 nm;

a surface energy of less than 45 mN/m; or

a silicone content of less than 100 μg per barrel.

8. The pharmaceutical container of claim 1 , wherein the stopper is coated with a polymer selected from the group consisting of polytetrafluoroethylene (PTFE), densified expanded polytetrafluoroethylene (ePTFE), tetrafluoroethylene (TFE), tetrafluoroethylene-perfluoroethylene copolymer, tetrafluoroethylene-hexafluoropropylene copolymer, tetrafluoroethylene-ethylene copolymer, trichlorotrifluoroethylene, poly-vinylidene fluoride, polyvinyl fluoride, perfluoropropylvinylether, and perfluoroalkoxy polymers, as well as copolymers, blends and combinations thereof.

9. The pharmaceutical container of claim 1 , wherein the ratio of the break loose force (BLF) relative to the glide force (GF) is BLF/GF≤3 after accelerated aging for 105 days.

10. The pharmaceutical container of claim 1 , the pharmaceutical container exhibiting a maximum break loose and glide force of not more than 12 N during a break loose and glide force test.

11. The pharmaceutical container of claim 1 , wherein a surface roughness of the inner surface of the barrel declines from the stopper's start position to its end position by at least 3% of at least one of Ra roughness or Rms roughness.

12. The pharmaceutical container of claim 1 , wherein the stopper has a stopper compression SC of less than 0.1, wherein SC=(OD−ID)/OD, OD is equal to an outer diameter of the stopper, and ID is equal to an inner diameter of the barrel.

13. The pharmaceutical container of claim 1 , wherein the barrel is partially or entirely made of glass or a polymer.

14. The pharmaceutical container of claim 1 , wherein the inner surface of the barrel is uncoated.

15. The pharmaceutical container of claim 1 , further comprising a liquid composition contained within the barrel.

16. The pharmaceutical container of claim 15 , wherein the liquid composition comprises an active ingredient comprising at least one of a peptide, a protein, an antibody, an enzyme, a vaccine, a receptor, an immune inhibitory agent, an anti-cancer agent, an immune checkpoint inhibitor, or a TNFα antibody.

17. The pharmaceutical container of claim 1 , further comprising the stopper slidably received in the barrel.

18. A pharmaceutical container for drug delivery, comprising:

a barrel configured to slidably receive a stopper, the pharmaceutical container exhibiting a ratio of a break loose force (BLF) relative to a glide force (GF) of BLF/GF≤2 during a break loose and glide force test and a total glide force variation TGFV=GF max −GF min measured when the stopper is moved from a start position to its end position is TGFV<2 N, wherein the stopper has a circumferential surface with a water contact angle θ C and an inner surface of the barrel has a water contact angle θ I , wherein a ratio of θ C /θ I >0.9.

19. A method of treatment, comprising:

administering to a subject an effective amount of an active ingredient using a pharmaceutical container, the pharmaceutical container comprising:

a barrel configured to slidably receive a stopper, the container exhibiting a ratio of a break loose force (BLF) relative to a glide force (GF) of BLF/GF≤2 during a break loose and glide force test and a total glide force variation TGFV=GF max −GF min measured when the stopper is moved from a start position to its end position is TGFV<2 N, the stopper having a proximal end suitable for contacting a plunger rod, a distal end suitable for contacting a pharmaceutical composition, a circumferential surface at least partially suitable for contacting an inner surface of the barrel, and one or more annular protrusions contacting the inner surface of the barrel when the stopper moves in a distal direction, the one or more annular protrusions each having a rising edge and a falling edge in a proximal-distal direction, the rising edge of a most proximal annular protrusion and the inner surface of the barrel span angle X in the distal direction, the falling edge of a most distal annular protrusion and the inner surface span an angle A in a proximal direction, and the ratio X/A is at least 1.05, wherein the stopper has a circumferential surface with a water contact angle θ C and the inner surface of the barrel has a water contact angle θ I , wherein a ratio of θ C /θ I >0.9.

20. A pharmaceutical container for drug delivery, comprising:

a barrel configured to slidably receive a stopper, the pharmaceutical container exhibiting a ratio of a break loose force (BLF) relative to a glide force (GF) of BLF/GF≤2 during a break loose and glide force test and a total glide force variation TGFV=GF max −GF min measured when the stopper is moved from a start position to its end position is TGFV<2 N, the stopper having a proximal end suitable for contacting a plunger rod, a distal end suitable for contacting a pharmaceutical composition, a circumferential surface at least partially suitable for contacting an inner surface of the barrel, and one or more annular protrusions contacting the inner surface of the barrel when the stopper moves in a distal direction, the one or more annular protrusions each having a rising edge and a falling edge in a proximal-distal direction, the rising edge of a most proximal annular protrusion and the inner surface of the barrel span angle X in the distal direction, the falling edge of a most distal annular protrusion and the inner surface span an angle A in a proximal direction, and the ratio X/A is at least 1.05, wherein the stopper has a stopper compression SC of less than 0.1, wherein SC=(OD-ID)/OD, OD is equal to an outer diameter of the stopper, and ID is equal to an inner diameter of the barrel.

21. A pharmaceutical container for drug delivery, comprising:

a barrel configured to slidably receive a stopper, the pharmaceutical container exhibiting a ratio of a break loose force (BLF) relative to a glide force (GF) of BLF/GF≤2 during a break loose and glide force test and a total glide force variation TGFV=GF max −GF min measured when the stopper is moved from a start position to its end position is TGFV<2 N, wherein the stopper has a stopper compression SC of less than 0.1, wherein SC=(OD-ID)/OD, OD is equal to an outer diameter of the stopper, and ID is equal to an inner diameter of the barrel.

22. A method of treatment, comprising:

administering to a subject an effective amount of an active ingredient using a pharmaceutical container, the pharmaceutical container comprising:

a barrel configured to slidably receive a stopper, the container exhibiting a ratio of a break loose force (BLF) relative to a glide force (GF) of BLF/GF≤2 during a break loose and glide force test and a total glide force variation TGFV=GF max −GF min measured when the stopper is moved from a start position to its end position is TGFV<2 N, the stopper having a proximal end suitable for contacting a plunger rod, a distal end suitable for contacting a pharmaceutical composition, a circumferential surface at least partially suitable for contacting an inner surface of the barrel, and one or more annular protrusions contacting the inner surface of the barrel when the stopper moves in a distal direction, the one or more annular protrusions each having a rising edge and a falling edge in a proximal-distal direction, the rising edge of a most proximal annular protrusion and the inner surface of the barrel span angle X in the distal direction, the falling edge of a most distal annular protrusion and the inner surface span an angle A in a proximal direction, and the ratio X/A is at least 1.05, wherein the stopper has a stopper compression SC of less than 0.1, wherein SC=(OD-ID)/OD, OD is equal to an outer diameter of the stopper, and ID is equal to an inner diameter of the barrel.